Table 1 The chemotherapeutic regimens and major prognostic factors of the studies included

From: Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

  

Major prognostic factors, N(%)

 

Author and year of study

Regimens

N

Male sex

MWD

ECOG⩾2

Liver meta

Multiple meta

Follow-up (months)

Shildt et al (1983)

5-Fluorouracil

20

 

—

—

—

—

10.2

Shildt et al (1983)

Cyclophosphamide, 5-fluorouracil, doxorubicin

16

—

—

—

—

—

24.5

Raber et al (1991)

Cisplatin, 5-fluorouracil, etoposide

46

—

26 (56.5)

2 (4.3)

—

—

—

Gill et al (1991)

Cisplatin, etoposide

16

9 (56.3)

6 (37.5)

—

5 (31.3)

10 (62.5)

28.75

Briasoulis et al (1998)

Carboplatin, etoposide, epirubicin

45

—

—

—

—

—

40

Parnis et al (2000)

Cisplatin, 5-fluorouracil, epirubicin

43

27 (62.8)

—

7 (16.3)

16 (37.2)

31 (72.1)

54

Briasoulis et al (2000)

Carboplatin, paclitaxel

33

18 (54.5)

22 (66.7)

—

—

—

47

Dowell et al (2001)

Carboplatin, etoposide

17

10 (58.8)

14 (82.4)

6 (35.3)

11 (64.7)

11 (64.7)

17.3

Dowell et al (2001)

Paclitaxel, 5-fluorouracil, leucovorin

17

10 (58.8)

11 (64.7)

3 (17.6)

10 (58.8)

10 (58.8)

16

Guardiola et al (2001)

Cisplatin, doxorubicin, cyclophosphamide

22

13 (59.1)

8 (36.4)

—

6 (27.3)

12 (54.5)

56.9

Greco et al (2001)

Carboplatin, paclitaxel, etoposide

71

35 (49.3)

34 (47.9)

12 (16.9)

—

43 (60.6)

50

Greco et al (2001)

Cisplatin, docetaxel

26

13 (50.0)

13 (50.0)

6 (23.1)

—

19 (73.1)

33

Greco et al (2001)

Carboplatin, docetaxel

47

25 (53.2)

18 (38.3)

12 (25.5)

—

32 (68.1)

24

Saghatchian et al (2001)

Cisplatin, etoposide, ifosfamide, bleomycin

30

15 (50.0)

0 (0)

7 (23.3)

3 (10)

17 (56.7)

32

Saghatchian et al (2001)

Cisplatin, 5-fluorouracil, interferon

18

6 (33.3)

18 (100)

1 (5.6)

6 (33.3)

8 (44.4)

32

Macdonald et al (2002)

Cisplatin, 5-fluorouracil, mitomycin

31

18 (58.1)

22 (71.0)

5 (16.1)

7 (22.6)

16 (51.6)

53

Greco et al (2002)

Carboplatin, paclitaxel, gemcitabine

120

64 (53.3)

63 (52.5)

16 (13.3)

51 (42.5)

78 (65)

27

Culine et al (2003)

Cisplatin, gemcitabine

39

26 (66.7)

26 (66.7)

6 (15.4)

21 (53.8)

29 (74.4)

22

Culine et al (2003)

Cisplatin, irinotecan

40

18 (45.0)

24 (60.0)

7 (17.5)

21 (52.5)

30 (75.0)

22

Assersohn et al (2003)

5-Fluorouracil

45

28 (62.2)

15 (33.3)

12 (26.7)

30 (66.7)

22 (48.9)

24

Assersohn et al (2003)

5-Fluorouracil, mitomycin

43

20 (46.5)

18 (41.9)

15 (34.9)

21 (48.8)

17 (39.5)

24

Balana et al (2003)

Cisplatin, gemcitabine, etoposide

40

25 (62.5)

15 (37.5)

4 (10.0)

6 (15.0)

27 (67.5)

29

Mukai et al (2003)

Cisplatin, docetaxel

5

1 (20.0)

4 (80.0)

1 (20.0)

—

—

—

Piga et al (2004)

Carboplatin, etoposide, doxorubicin

102

54 (52.9)

38 (37.3)

8 (7.8)

27 (26.5)

89 (87.3)

60

Pouessel et al (2004)

Docetaxel, gemcitabine

36

23 (63.9)

16 (44.4)

3 (8.3)

15 (41.7)

26 (72.2)

32

Park et al (2004)

Cisplatin, paclitaxel

37

20 (54.1)

31 (83.8)

8 (21.6)

12 (32.4)

35 (94.6)

31.5

El-Rayes et al (2005)

Carboplatin, paclitaxel

22

13 (59.1)

15 (68.2)

2 (9.1)

17 (77.3)

—

23.2

Palmeri et al (2006)

Cisplatin, paclitaxel, gemcitabine

33

25 (75.8)

25 (75.8)

1 (3.0)

8 (24.2)

14 (42.4)

20.5

Palmeri et al (2006)

Cisplatin, gemcitabine, vinorelbine

33

27 (81.8)

23 (69.7)

1 (3.0)

10 (30.3)

15 (45.5)

21.5

Pittman et al (2006)

Carboplatin, gemcitabine

50

23 (46.0)

—

12 (24.0)

38 (76.0)

—

35

Schneider et al (2007)

Carboplatin, gemcitabine, capecitabine

33

19 (57.6)

22 (66.7)

9 (27.3)

20 (60.6)

10 (30.3)

54.1

Pentheroudakis et al (2008)

Carboplatin, docetaxel

23

12 (52.2)

—

3 (13.0)

9 (39.1)

13 (56.5)

48

Briasoulis et al (2008)

Oxaliplatin, irinotecan

47

33 (70.2)

19 (40.4)

11 (23.4)

27 (57.4)

27 (57.4)

35.5

Huebner et al (2009)

Carboplatin, paclitaxel

42

23 (54.8)

—

5 (11.9)

23 (54.8)

36 (85.7)

26

Huebner et al (2009)

Gemcitabine, vinorelbine

45

27 (60.0)

—

10 (22.2)

29 (64.4)

37 (82.2)

22

Schuette et al (2009)

Oxaliplatin, capecitabine

51

35 (68.6)

7 (13.7)

5 (9.8)

20 (39.2)

—

24

Yonemori et al (2009)

Carboplatin, irinotecan

45

23 (51.1)

21 (46.7)

4 (8.9)

8 (17.8)

32 (71.1)

48

Hainsworth et al (2009)

Carboplatin, paclitaxel, bevacizumab, erlotinib

60

29 (48.3)

31 (51.7)

0

—

30 (50.0)

25

Mukai et al (2010)

Cisplatin, docetaxel

45

23 (51.1)

19 (42.2)

6 (13.3)

—

10 (22.2)

57.1

Moller et al (2010)

Cisplatin, paclitaxel, gemcitabine

98

51 (52.0)

—

0

49 (50.0)

53 (54.1)

80

Hainsworth et al (2010)

Carboplatin, paclitaxel, etoposide, gefitinib

93

44 (47.3)

49 (52.7)

9 (9.7)

50 (53.8)

75 (80.6)

60

Hainsworth et al (2010)

Gemcitabine, irinotecan, gefitinib

105

63 (60.0)

56 (53.3)

8 (7.6)

54 (51.4)

73 (69.5)

60

  1. Abbreviations: ECOG=Eastern Cooperative Oncology Group performance status; meta=metastasis; MWD=moderate- to well-differentiated adenocarcinoma.
Back to article page